Sanofi India Ltd Stock Analysis

BSE: 500674 | NSE: SANOFI | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 22-Sep-2023 18:01
7114.05 -34.60 (-0.48%)

DeciZen - Make an Informed Decision on Sanofi India

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Semi Strong

Sanofi India Price Chart

P/E Ratio ( SA) :
Market Cap :
16,463.8 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Sanofi India Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanofi India Ltd is a good quality company.

2. Is Sanofi India Ltd undervalued or overvalued?

The key valuation ratios of Sanofi India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Sanofi India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sanofi India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Sanofi India:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sanofi India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 19.1%15.5%16.9%17.3%16.5%17.8%19.6%22.4%27.5%30.2%-
Value Creation Index

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,8091,9772,1932,3672,4642,7713,0712,9022,9572,7702,806
YoY Gr. Rt. %-9.3%10.9%7.9%4.1%12.5%10.8%-5.5%1.9%-6.3%-
Adj EPS 105.495.4114.3131.3139.9163.5197.9220.9259.2229.4249.7
YoY Gr. Rt. %--9.5%19.8%14.9%6.6%16.8%21.1%11.6%17.4%-11.5%-
BVPS (₹) 580.3643.7707.3810.7869.9950.21,043.5897.8941.5527.7314.5
Adj Net Profit 243220263302322377456509597528575
Cash Flow from Ops. 273265213322435374412611559399-
Debt/CF from Ops. 0000000000-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.9%2.4%-3.4%-6.3%
Adj EPS 9%10.4%5%-11.5%
Share Price 11.3% 1.9% -5.2% 19.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 1915.516.917.216.517.719.622.327.530.259.3
Op. Profit Mgn % 2217.32122.621.922.621.724.725.825.427
Net Profit Mgn % 13.411.11212.813.113.614.917.520.219.120.5
Debt to Equity 00000000000
Working Cap Days 122151149156287379386419436470131
Cash Conv. Cycle 38423950312018132139

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 59.30%

Sales growth has been subdued in last 3 years -3.37%

Net Profit has been subdued in last 3 years 5.03%

Sales growth is not so good in last 4 quarters at -1.37%

Latest Financials - Sanofi India Ltd.

Standalone Consolidated
TTM EPS (₹) 249.7 67.7
TTM Sales (₹ Cr.) 2,806 743
BVPS (₹.) 314.5 0
Reserves (₹ Cr.) 701 683
P/BV 22.73 0.00
PE 28.63 105.66
From the Market
52 Week Low / High (₹) 5240.00 / 7587.95
All Time Low / High (₹) 235.05 / 9300.00
Market Cap (₹ Cr.) 16,464
Equity (₹ Cr.) 23
Face Value (₹) 10
Industry PE 42.2

Management X-Ray of Sanofi India :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Sanofi India

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Sanofi India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Sanofi India on 22-Sep-2023 18:01 is : 7,114.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2023 18:01 the market cap of Sanofi India stood at ₹ 16,463.8.
The latest PE ratio of Sanofi India as of 22-Sep-2023 18:01 is 28.63.
The latest PB ratio of Sanofi India as of 22-Sep-2023 18:01 is 22.73
The 52-week high of Sanofi India is ₹ 7,588 and the 52-week low is ₹ 5,240.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Sanofi India is ₹ 2,806 ( Cr.) .

About Sanofi India Ltd

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.

Business area of the company

The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.


Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).

Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)

Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,


  • 2013: Sanofi India launches Combiflam Plus.
  • 2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
  • 2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
  • 2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
  • 2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
  • 2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
  • 2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
  • 2018: Sanofi receives positive CHMP opinion for dengue vaccine.
  • 2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
  • 2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
  • 2020: Sanofi Completes Acquisition of Synthorx, Inc.
  • 2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
  • 2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now